# Primary Cells Market

> Primary Cells Market Research Report Information By Source (Hematopoietic Cells, Skin Cells, Gastrointestinal Cells, Liver Cells, Lung Cells, and Skeletal and Muscle Cells) by Type (Human Primary Cells and Animal Primary Cells), By End User (Pharmaceutical and Biotechnology Companies and Research Institutes), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.25%
- **2024:** $ 2.06 Billion
- **2025:** $ 2.25 Billion
- **2035:** $ 5.45 Billion
- **Key Players:** Thermo Fisher Scientific (US), Merck KGaA (DE), Lonza Group (CH), Corning Incorporated (US), Becton Dickinson and Company (US), Promega Corporation (US), F. Hoffmann-La Roche Ltd (CH), Sigma-Aldrich (US), Cell Signaling Technology (US)These companies actively shape the primary human cell market and broader primary cells market trends through innovation and strategic expansion.

**Report ID:** MRFR/LS/4835-CR · **Pages:** 78 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** March 09, 2026

**URL:** https://www.marketresearchfuture.com/reports/primary-cells-market-6296

---

## Market Summary

## **Global Primary Cells Market Overview**

Primary Cells Market Size was valued at USD 1.83 Billion in 2023. The Global Primary Cells industry is projected to grow from USD 2.06 Billion in 2024 to USD 4.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.25% during the forecast period (2024 - 2032).

Increased cancer frequency, increasing government funding for cancer research, and building new infrastructure to support the healthcare industry are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Primary Cells Market Trends**

Due to increased cancer research and the creation of novel cures and treatments, the demand for primary cells has been increasing. With no proven dependable cure and few known causes of its genesis, cancer has been the deadliest and most enduring type of sickness in the world. As a result, research into the disease has continued and expanded for many years. The field of cancer research has been greatly benefited and widened by advances in biochemistry and medically related apparatus, like improved microscopes and chemicals.

The development of efficient therapeutics using primary cells to treat a range of immunodeficiency illnesses is propelling the worldwide market for primary cells at a rapid rate thanks to significant expenditures in R&D efforts. Medical researchers are continuously attempting to treat malignant malignancies utilizing primary cells from an animal or human tissue due to the rise of the biotechnology and biopharmaceutical sectors. The primary cell market is expanding because of the utilization of patient-derived samples in cutting-edge preclinical technologies including 3D cell cultures.

Additionally, primary human cells are increasingly favored over animal cells for researching how cancer cells affect the human body. Thus, this factor is driving the market CAGR. 

**Figure 1: Number of cancer cases by 2030**

****

Source: Secondary and Primary Research, _Market Research Future_ Database and Analyst Review

The global market for primary cells has been steadily expanding, related to the rise in cancer cases everywhere. Due to their advantages over cell lines, primary cells are employed for cancer cell discovery and medication screening, driving market expansion. Furthermore, because cancer is acknowledged as the leading cause of death worldwide, governments and private institutions all over the globe are quickly investing in new healthcare technologies for successful cancer treatment, providing momentum to the primary cell market expansion.

Primary cells are used in extensive research activities to create pertinent medications and procedures, such as cell and regenerative therapies, to cure cancer patients. Thus, it is anticipated that this aspect will accelerate Primary Cells market revenue globally.

## **Primary Cells Market Segment Insights**

### **Primary Cells Source Insights**

Based on the Source, the Primary Cells Market segmentation includes Hematopoietic Cells, Skin Cells, Gastrointestinal Cells, Liver Cells, Lung Cells, and Skeletal and Muscle Cells. The Hematopoietic Cells segment held the majority share in 2022 in the Primary Cells Market data. This can be attributed to the rising prevalence of blood cancer and the increasing number of stem cell research projects. Hematopoietic cells are used to understand the biochemical pathways of tumor cells and the efficacy of different drugs. As a result, this segment accounts for the largest market share.

### **Primary Cells Type Insights**

Based on type, the Primary Cells Market segmentation includes Human Primary Cells and Animal Primary cells. The Human primary cells segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The main drivers promoting the growth of this market are the expanding use of primary human cells in the creation of innovative cancer medicines and the rising funding for cell therapy R&D.

**Figure 2: Primary Cells Market, by Type, 2021 & 2032 (USD billion)**Source: Secondary and Primary Research, _Market Research Future_ Database and Analyst Review

### **Primary Cells End-user Insights**

Based on End-user, the Primary Cells Market segmentation includes Pharmaceutical and Biotechnology Companies and Research Institutes. The Pharmaceutical and Biotechnology Companies segment dominated the Primary Cells market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The product is being used by pharmaceutical and biotechnology firms for pharmaceutical drug discovery to treat genetic and autoimmune illnesses, damage, and inflammation. Pharmaceutical companies frequently use primary cells to test the cytotoxicity of novel medicines and drug carriers.

The market need for primary cells has grown from this niche as an alternative to using animal testing models to test novel medications and chemicals. 

### **Primary Cells Regional Insights**

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Primary Cells market accounted for USD 0.27 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. The primary cell culture market was dominated by North America, which accounted for the biggest revenue share of 45.80% in 2021 and is anticipated to maintain this pattern during the forecast period.

The high cost of healthcare, expanding senior population, increasing prevalence of chronic illnesses, and support government financing are all contributing factors to the Region's rise. The Region's market is also expanding due to market participants' increased focus on developing novel cell culture applications, instrumentation, the availability of various cell types, and their cellular interactions.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 3: PRIMARY CELLS MARKET SHARE BY REGION 2021 (%)**Source: Secondary and Primary Research, _Market Research Future_ Database and Analyst Review

Throughout the projected period, the Asia Pacific Primary cells market is anticipated to have the quickest growth. The reduced prices for stem cell transplantation in the area, which also contribute to the strong demand, are the main cause of the rise. Significant R&D activities are also being carried out by researchers, which is another factor contributing to the expansion of the Region. For instance, in March 2020, scientists at China's Centre for Disease Control (CDC) propagated SARS-CoV-2 using lung airway cells grown in human tissue culture systems.

Further, the China Primary Cells market held the largest market share, and the India Primary Cells market was the fastest growing market in the region.

Regarding worth, Europe's Primary cells market is now holding Third place. Europe continues to place a lot of emphasis on the healthcare sector. Many initiatives have been introduced to enhance the Region's medical services. The developed economies of Europe offer market participants appealing growth prospects. According to the Bureau for National Statistics, the gross domestic spending on R&D activities was more than xx billion euros in 2021. Moreover, the UK Primary Cells market held the largest market share, and the Germany Primary Cells market was the fastest-growing market in the Region.

**Primary Cells Key Market Players & Competitive Insights**

Major market players are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for the Primary Cells industry. With significant industry changes, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market participants are also undertaking various strategic activities to expand their global presence. In order to grow and remain in a market that is becoming more and more competitive, Primary Cells industry competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the main business tactics used by the Primary Cells industry to serve customers and increase the market sector. The Primary Cells industry has recently given medicine some of the most important advantages. The Primary Cells markets major players such as AllCells (US),  ZenBio Inc. (Research Triangle Park NC),   PromoCell (UK),  Thermo Fisher Scientific Inc. (US),  Cell Biologics Inc. (Chicago), STEMCELL Technologies Inc. (Canada),  Merck KGaA (Germany), American Type Culture Collection (ATCC), AG (Switzerland), and others are working on expanding the market demand by investing in research and development activities.

An American provider of scientific equipment, reagents, and consumables, as well as software services, is Thermo Fisher Scientific Inc. Thermo Fisher, headquartered in Waltham, Massachusetts, was created in 2006 by the union of Thermo Electron and Fisher Scientific. Thermo Fisher Scientific Inc., for instance, introduced a novel medium for developing human T cells for allogeneic cell treatments in January 2021. The new Gibco CTS OpTmizer Pro SFM aids in promoting the multiplication of donor T (lymphocyte) cells. It is a revolutionary media option for efficiently producing cost-effective cell treatments by focusing on the metabolism of healthy donors.

The Lonza Group is a Basel-based international manufacturer of products for the pharmaceutical, biotechnology, and nutrition industries. It has significant operations in North America, South Asia, and North Europe. Lonza was founded in the late 19th century in Switzerland with that name. Lonza and AllCells signed a private cooperation agreement in February 2019. This partnership was carried out to produce a wide variety of primary hematopoietic cells after commercialization. This collaboration increased Lonza's product line and gave cell biologists simple access to a variety of high-quality cells that were accessible and suitable for their study.

**Key Companies in the Primary Cells market include**

### Primary Cells Market Industry Developments

- **Q2 2024: Lonza Expands Primary Cell Manufacturing Capacity with New Facility in Portsmouth, NH** Lonza announced the opening of a new manufacturing facility in Portsmouth, New Hampshire, dedicated to the production of primary cells and cell therapy products, aiming to meet growing demand from pharmaceutical and biotech clients.
- **Q2 2024: Thermo Fisher Scientific Launches New Primary Human Hepatocyte Cell Line for Drug Discovery** Thermo Fisher Scientific introduced a new primary human hepatocyte cell product designed to improve the accuracy of preclinical drug metabolism and toxicity studies for pharmaceutical companies.
- **Q2 2024: PromoCell Announces Strategic Partnership with Merck KGaA for Primary Cell Distribution in Europe** PromoCell entered into a distribution agreement with Merck KGaA to expand access to its portfolio of primary human cells and cell culture media across European research institutions.
- **Q3 2024: BioIVT Acquires Cellero to Expand Primary Cell and Immune Cell Offerings** BioIVT completed the acquisition of Cellero, a provider of human primary cells and immune cell products, strengthening its position in the primary cell market and expanding its product portfolio for research and clinical applications.
- **Q3 2024: STEMCELL Technologies Receives FDA Clearance for Primary Cell-Based Diagnostic Kit** STEMCELL Technologies announced FDA clearance for its new diagnostic kit utilizing primary human cells, enabling more accurate detection of hematological disorders in clinical laboratories.
- **Q3 2024: Lonza Signs Multi-Year Supply Agreement with Major Pharma for Primary Cell Products** Lonza entered into a multi-year contract with a leading pharmaceutical company to supply primary human cells for use in drug discovery and development pipelines.
- **Q4 2024: AllCells Opens New GMP-Compliant Facility for Primary Cell Processing in California** AllCells inaugurated a new Good Manufacturing Practice (GMP)-compliant facility in Alameda, California, to enhance its capacity for processing and supplying primary human cells for cell therapy and research.
- **Q4 2024: Cyagen Launches Primary Human Neural Cell Product Line for Neuroscience Research** Cyagen announced the commercial launch of a new line of primary human neural cells, targeting academic and pharmaceutical neuroscience research markets.
- **Q1 2025: BioIVT Appoints New CEO to Drive Growth in Primary Cell and Biospecimen Markets** BioIVT named a new Chief Executive Officer, citing plans to accelerate expansion in the primary cell and biospecimen sectors through strategic investments and partnerships.
- **Q1 2025: PromoCell Receives EMA Approval for Primary Cell-Based Therapy Product** PromoCell secured European Medicines Agency (EMA) approval for its first primary cell-based therapy, marking a significant regulatory milestone for the company in the regenerative medicine field.
- **Q2 2025: Thermo Fisher Scientific Acquires Small Biotech Specializing in Primary Cell Isolation Technologies** Thermo Fisher Scientific completed the acquisition of a biotech startup focused on innovative primary cell isolation methods, aiming to enhance its cell and gene therapy solutions portfolio.
- **Q2 2025: STEMCELL Technologies Raises $100M to Expand Primary Cell R&D and Manufacturing** STEMCELL Technologies closed a $100 million funding round to scale up research and manufacturing capabilities for its primary cell products, supporting growth in cell therapy and regenerative medicine markets.

## **Primary Cells Market Segmentation**

### **Primary Cells Source Outlook**

### **Primary Cells Type Outlook**

### **Primary Cells End User Outlook**

### **Primary Cells Regional Outlook**

## Market Drivers

### Rising Demand for Biopharmaceuticals

The rising demand for biopharmaceuticals is significantly impacting the Primary Cells Market. As the biopharmaceutical sector continues to expand, driven by the need for novel therapies and biologics, the reliance on primary cells for research and production processes is becoming more pronounced. Primary cells are essential for the development of biologics, including monoclonal antibodies and vaccines, as they provide a more accurate representation of human biology. The biopharmaceutical market is projected to exceed 500 billion dollars by 2025, indicating a substantial opportunity for the Primary Cells Market to meet the increasing needs of this sector. This trend suggests that the growth of biopharmaceuticals will likely correlate with a heightened demand for primary cells, further solidifying their importance in the industry.

### Increased Focus on Personalized Medicine

The increased focus on personalized medicine is emerging as a key driver for the Primary Cells Market. As healthcare shifts towards more tailored treatment approaches, the demand for primary cells that can provide insights into individual patient responses is growing. Primary cells are invaluable in the development of personalized therapies, as they allow for the study of patient-specific cellular behavior and drug responses. The personalized medicine market is expected to reach approximately 2 trillion dollars by 2025, highlighting the potential for primary cells to play a central role in this transformation. This trend indicates that the Primary Cells Market is likely to benefit from the increasing emphasis on personalized healthcare solutions, as researchers and clinicians seek to optimize treatment efficacy.

### Growing Applications in Regenerative Medicine

The applications of primary cells in regenerative medicine are expanding, thereby driving the growth of the Primary Cells Market. As the field of regenerative medicine evolves, the need for authentic cellular models becomes increasingly critical. Primary cells are preferred over immortalized cell lines due to their ability to closely mimic in vivo conditions. This is particularly relevant in the development of cell-based therapies and tissue engineering. The regenerative medicine market is anticipated to reach over 100 billion dollars by 2025, with primary cells playing a crucial role in this growth. The increasing focus on developing effective treatments for chronic diseases and injuries is likely to further enhance the demand for primary cells, positioning the Primary Cells Market favorably in the coming years.

### Increasing Research and Development Activities

The Primary Cells Market is experiencing a surge in research and development activities, driven by the need for innovative therapeutic solutions. This trend is particularly evident in the fields of regenerative medicine and drug discovery, where primary cells are essential for understanding cellular mechanisms and testing drug efficacy. According to recent data, the investment in R&D within the life sciences sector has seen a notable increase, with expenditures reaching approximately 200 billion dollars annually. This growing focus on R&D is likely to propel the demand for primary cells, as researchers seek reliable and physiologically relevant models to advance their studies. Consequently, the expansion of R&D activities is expected to significantly influence the growth trajectory of the Primary Cells Market.

### Technological Advancements in Cell Isolation Techniques

Technological advancements in cell isolation techniques are playing a pivotal role in shaping the Primary Cells Market. Innovations such as microfluidics and magnetic-activated cell sorting are enhancing the efficiency and purity of primary cell isolation. These advancements not only improve the quality of the cells obtained but also reduce the time and costs associated with cell preparation. As a result, researchers are increasingly adopting these advanced techniques, which could lead to a higher demand for primary cells in various applications, including drug development and personalized medicine. The market for cell isolation technologies is projected to grow at a compound annual growth rate of around 10%, indicating a robust potential for the Primary Cells Market to capitalize on these advancements.

## Future Outlook

The Primary Cells Market is projected to grow at a 9.25% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for portable devices, and sustainable energy solutions.

**New opportunities:**

- Development of biodegradable primary cells for eco-friendly applications. Expansion into emerging markets with tailored product offerings. Investment in R&D for high-capacity primary cell technologies.

By 2035, the Primary Cells Market is expected to achieve substantial growth, reflecting evolving consumer needs and technological innovations.

## Segment Insights

### By Source: Hematopoietic Cells (Largest) vs. Skin Cells (Fastest-Growing)

In the Primary Cells Market, [Hematopoietic Cells](https://www.marketresearchfuture.com/reports/hematopoietic-stem-cell-transplantation-market-21548) represent the largest segment, leveraging their widespread application in therapeutic treatments, particularly in hematocellular diseases and regenerative medicine. These cells are crucial for blood-related treatments, which significantly contribute to their dominant market share. Conversely, Skin Cells are emerging as the fastest-growing segment, driven by advancements in regenerative medicine and skin-related therapies, including burns and wound healing, highlighting the increasing demand for effective treatment options. The growth of Hematopoietic Cells is sustained by ongoing research and development in cell therapies and stem cell treatments. On the other hand, the rising prevalence of skin disorders and an aging population are propelling the market for Skin Cells. This segment sees significant investment for innovative treatments, which catalyzes its rapid growth in the forecasted period, reflecting a shift in healthcare priorities towards personalized medicine and advanced regenerative solutions.

Hematopoietic Cells (Dominant) vs. Skeletal and Muscle Cells (Emerging)

Hematopoietic Cells are recognized as the dominant source within the Primary Cells Market, widely utilized for their therapeutic applications, particularly in bone marrow transplants and treatment of various blood disorders. Their robustness and versatility in therapeutic protocols ensure a stable demand, marking their significance in regenerative health. Conversely, Skeletal and Muscle Cells represent an emerging segment, garnering attention due to the rising interest in muscle regeneration and repair therapies, especially in sports medicine and rehabilitation. As research continues to explore the potential of these cells for muscle-related conditions, their market position is expected to gradually strengthen.

### By Type: Human Primary Cells (Largest) vs. Animal Primary Cells (Fastest-Growing)

The Primary Cells Market is composed of two significant segments: Human Primary Cells and Animal Primary Cells. Currently, Human Primary Cells hold the largest market share, largely due to their extensive use in various biomedical applications, including drug discovery and regenerative medicine. On the other hand, Animal Primary Cells represent a growing portion of the market, driven by their increasing applications in vaccine development and toxicological studies. The balance between these two segments showcases the diverse applications and preferences of researchers and manufacturers in the field of cell biology.

In terms of growth trends, the demand for Human Primary Cells remains strong, primarily fueled by advancements in personalized medicine and the push for more effective therapies. Meanwhile, Animal Primary Cells are gaining traction, spurred by rising investments in pharmaceutical research and the need for more relevant animal models in preclinical testing. As regulatory standards continue to evolve, the inclination towards Animal Primary Cells is expected to increase, indicating a dynamic shift within the segment as research methodologies adapt and expand in scope.

Human Primary Cells: (Dominant) vs. Animal Primary Cells (Emerging)

Human Primary Cells are recognized as the dominant players in the Primary Cells Market, owing to their versatility and essential role in understanding human physiology and disease mechanisms. They are extensively used in research fields ranging from cancer studies to immunology, providing critical insights that are pertinent to human health. The established infrastructure for sourcing and utilizing these cells further solidifies their market position, making them a preferred choice for many research institutions and pharmaceutical companies.

Conversely, Animal Primary Cells are emerging rapidly, driven by the increasing need for accurate animal models that better simulate human disease responses. Their application in vaccine production and drug testing has garnered significant attention, leading to a growing investment in their research and development. As scientists strive for more ethically viable and scientifically sound methods, Animal Primary Cells are becoming integral in bridging the gap between laboratory findings and clinical applications, thus carving their niche in the market.

### By End User: Pharmaceutical and Biotechnology Companies (Largest) vs. Research Institutes (Fastest-Growing)

In the Primary Cells Market, the distribution of market share is predominantly led by Pharmaceutical and Biotechnology Companies dominate the primary cells market application segment. Meanwhile, Research Institutes are expanding rapidly, particularly in regions such as germany primary cells market by end user and south korea primary cells market by end user. Research Institutes, while smaller in overall share, are rapidly gaining traction as they increasingly adopt primary cells for innovative research and development purposes. This adoption is fundamental in enhancing experimental outcomes and advancing personalized medicine agendas within the healthcare sector.

Pharmaceutical and Biotechnology Companies (Dominant) vs. Research Institutes (Emerging)

Pharmaceutical and Biotechnology Companies represent the dominant force in the Primary Cells Market due to their extensive reliance on primary cells for drug development and testing. Their focus on biopharmaceutical innovation drives significant investments in cellular technologies to improve therapeutic efficacy. Conversely, Research Institutes stand as the emerging players within the market, tapping into the potential of primary cells for pioneering studies that explore novel therapeutic avenues, regenerative medicine, and disease modeling. Both segments play pivotal roles, with pharmaceutical companies leading the market while research institutes contribute to its growth through innovative applications.

## Regional Market Share Analysis

### North America : Innovation and Research Hub

North America remains the largest contributor to the primary cells global market, followed by Europe and Asia-Pacific. Regional developments include france primary cells market by source, germany primary cells market by end user, and japan primary cells market by source, reflecting strong geographic segmentation within the primary cell culture market. Regional developments include France primary cells market by source, Germany primary cells market by end user, and japan primary cells market by source, reflecting strong geographic segmentation within the primary cell culture market. The presence of leading biotechnology firms and academic institutions further fuels market expansion, with a focus on innovative cell therapies and regenerative medicine. The United States dominates this market, accounting for a significant portion of the demand, followed by Canada. Key players such as Thermo Fisher Scientific, Becton Dickinson, and Corning Incorporated are pivotal in driving advancements in primary cell technologies. The competitive landscape is characterized by continuous innovation and strategic partnerships aimed at enhancing product offerings and market reach.

### Europe : Regulatory Framework and Growth

Europe is the second-largest market for primary cells, holding around 30% of the global share. The region benefits from stringent regulatory standards that ensure product quality and safety, which in turn drives market growth. Increasing investments in biotechnology and healthcare, along with a rising prevalence of chronic diseases, are key factors contributing to the demand for primary cells in Europe. Germany and the United Kingdom are the leading countries in this market, with a strong presence of key players like Merck KGaA and Lonza Group. The competitive landscape is marked by collaborations between industry and academia, fostering innovation in cell-based therapies. The European Medicines Agency plays a crucial role in regulating and approving new cell therapies, ensuring compliance with safety standards.

### Asia-Pacific : Emerging Market with Potential

Asia-Pacific is an emerging powerhouse in the primary cells market, accounting for approximately 20% of the global share. The region is witnessing rapid growth due to increasing investments in healthcare infrastructure, rising awareness of cell-based therapies, and a growing population with healthcare needs. Countries like China and India are at the forefront, driven by government initiatives to boost biotechnology and healthcare sectors. China is the largest market in the region, followed by Japan and India. The competitive landscape is evolving, with both local and international players, including Corning Incorporated and Sigma-Aldrich, expanding their presence. The region's market dynamics are influenced by a mix of established companies and startups focusing on innovative cell technologies, creating a vibrant ecosystem for growth.

### Middle East and Africa : Resource-Rich with Challenges

The Middle East and Africa represent a developing market for primary cells, holding about 5% of the global share. The growth in this region is driven by increasing healthcare investments, a rising prevalence of diseases, and a growing interest in regenerative medicine. However, challenges such as limited infrastructure and regulatory hurdles can impede market expansion. Countries like South Africa and the UAE are leading the way in adopting advanced healthcare solutions. South Africa is the largest market in the region, with a focus on improving healthcare access and quality. The competitive landscape is characterized by a mix of local and international players, with companies like F. Hoffmann-La Roche and Promega Corporation making significant inroads. The region's potential for growth is substantial, particularly as governments prioritize healthcare improvements and biotechnology advancements.

## Competitive Benchmarking

The primary cells market ppt landscape reflects a moderately fragmented but innovation-driven ecosystem. Strategic acquisitions, R&D expansion, and regulatory approvals continue shaping the primary human cell market and broader primary cells global market. Key players such as Thermo Fisher Scientific (US), Merck KGaA (DE), and Lonza Group (CH) are actively shaping the market through their operational strategies. Thermo Fisher Scientific (US) emphasizes innovation in product development, particularly in cell culture technologies, which positions it favorably against competitors. Merck KGaA (DE) focuses on expanding its global footprint, enhancing its supply chain capabilities to meet increasing demand. Meanwhile, Lonza Group (CH) is leveraging strategic partnerships to enhance its service offerings, particularly in the biopharmaceutical sector, thereby influencing the competitive dynamics of the market. The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Primary Cells Market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation and quality improvements across the sector. In August 2025, Thermo Fisher Scientific (US) announced the launch of a new line of primary cell culture products aimed at enhancing research capabilities in regenerative medicine. This strategic move is likely to solidify its market position by addressing the growing demand for advanced cell culture solutions, thereby attracting a broader customer base. The introduction of these products not only reflects the company's commitment to innovation but also its responsiveness to emerging research trends. In July 2025, Merck KGaA (DE) completed the acquisition of a biotechnology firm specializing in cell-based assays, which is expected to enhance its portfolio in the life sciences sector. This acquisition appears to be a strategic maneuver to bolster its capabilities in high-demand areas, potentially increasing its market share and reinforcing its competitive edge. By integrating these advanced technologies, Merck KGaA (DE) is likely to offer more comprehensive solutions to its clients, thereby enhancing customer loyalty and satisfaction. In September 2025, Lonza Group (CH) entered into a strategic partnership with a leading academic institution to develop innovative cell therapies. This collaboration is indicative of a broader trend towards academia-industry partnerships, which may accelerate the pace of innovation in the Primary Cells Market. By aligning with academic research, Lonza Group (CH) is positioned to leverage cutting-edge discoveries, potentially leading to the development of novel therapeutic solutions that could redefine treatment paradigms. As of October 2025, the Primary Cells Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in research and development processes. These trends are reshaping competitive strategies, with companies increasingly forming strategic alliances to enhance their technological capabilities and market reach. The shift from price-based competition to a focus on innovation, technology, and supply chain reliability is becoming evident, suggesting that future competitive differentiation will hinge on the ability to deliver advanced, reliable, and sustainable solutions.

## Recent News & Developments

- **Recent developments by Lonza Group, Thermo Fisher Scientific**, and Merck KGaA continue to strengthen the competitive landscape of the primary cells market and primary cells market analysis outlook.
- **Q2 2024: Lonza Expands Primary Cell Manufacturing Capacity with New Facility in Portsmouth, NH** Lonza announced the opening of a new manufacturing facility in Portsmouth, New Hampshire, dedicated to the production of primary cells and cell therapy products, aiming to meet growing demand from pharmaceutical and biotech clients.
- **Q2 2024: Thermo Fisher Scientific Launches New Primary Human Hepatocyte Cell Line for Drug Discovery** Thermo Fisher Scientific introduced a new primary human hepatocyte cell product designed to improve the accuracy of preclinical drug metabolism and toxicity studies for pharmaceutical companies.
- **Q2 2024: PromoCell Announces Strategic Partnership with Merck KGaA for Primary Cell Distribution in Europe** PromoCell entered into a distribution agreement with Merck KGaA to expand access to its portfolio of primary human cells and cell culture media across European research institutions.
- **Q3 2024: BioIVT Acquires Cellero to Expand Primary Cell and Immune Cell Offerings** BioIVT completed the acquisition of Cellero, a provider of human primary cells and immune cell products, strengthening its position in the primary cell market and expanding its product portfolio for research and clinical applications.
- **Q3 2024: STEMCELL Technologies Receives FDA Clearance for Primary Cell-Based Diagnostic Kit** STEMCELL Technologies announced FDA clearance for its new diagnostic kit utilizing primary human cells, enabling more accurate detection of hematological disorders in clinical laboratories.
- **Q3 2024: Lonza Signs Multi-Year Supply Agreement with Major Pharma for Primary Cell Products** Lonza entered into a multi-year contract with a leading pharmaceutical company to supply primary human cells for use in drug discovery and development pipelines.
- **Q4 2024: AllCells Opens New GMP-Compliant Facility for Primary Cell Processing in California** AllCells inaugurated a new Good Manufacturing Practice (GMP)-compliant facility in Alameda, California, to enhance its capacity for processing and supplying primary human cells for cell therapy and research.
- **Q4 2024: Cyagen Launches Primary Human Neural Cell Product Line for Neuroscience Research** Cyagen announced the commercial launch of a new line of primary human neural cells, targeting academic and pharmaceutical neuroscience research markets.
- **Q1 2025: BioIVT Appoints New CEO to Drive Growth in Primary Cell and Biospecimen Markets** BioIVT named a new Chief Executive Officer, citing plans to accelerate expansion in the primary cell and biospecimen sectors through strategic investments and partnerships.
- **Q1 2025: PromoCell Receives EMA Approval for Primary Cell-Based Therapy Product** PromoCell secured European Medicines Agency (EMA) approval for its first primary cell-based therapy, marking a significant regulatory milestone for the company in the regenerative medicine field.
- **Q2 2025: Thermo Fisher Scientific Acquires Small Biotech Specializing in Primary Cell Isolation Technologies** Thermo Fisher Scientific completed the acquisition of a biotech startup focused on innovative primary cell isolation methods, aiming to enhance its cell and gene therapy solutions portfolio.
- **Q2 2025: STEMCELL Technologies Raises $100M to Expand Primary Cell R&D and Manufacturing** STEMCELL Technologies closed a $100 million funding round to scale up research and manufacturing capabilities for its primary cell products, supporting growth in cell therapy and regenerative medicine markets.

## Report Scope

| MARKET SIZE 2024 | 2.06(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 2.251(USD Billion) |
| MARKET SIZE 2035 | 5.452(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.25% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2026 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Thermo Fisher Scientific (US), Merck KGaA (DE), Lonza Group (CH), Corning Incorporated (US), Becton Dickinson and Company (US), Promega Corporation (US), F. Hoffmann-La Roche Ltd (CH), Sigma-Aldrich (US), Cell Signaling Technology (US) |
| Segments Covered | Source, Type, End User, Region |
| Key Market Opportunities | Advancements in biomanufacturing techniques enhance efficiency in the Primary Cells Market. |
| Key Market Dynamics | Rising demand for renewable energy sources drives innovation in primary cell technologies and competitive market dynamics. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Primary Cells Market by 2035?**
A: The Primary Cells Market is projected to reach a valuation of 5.452 USD Billion by 2035.

**Q: What was the market valuation of the Primary Cells Market in 2024?**
A: In 2024, the market valuation of the Primary Cells Market was 2.06 USD Billion.

**Q: What is the expected CAGR for the Primary Cells Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Primary Cells Market during the forecast period 2025 - 2035 is 9.25%.

**Q: Which segment of the Primary Cells Market had the highest valuation in 2024?**
A: In 2024, the segment of Human Primary Cells had the highest valuation at 0.82 USD Billion.

**Q: What are the key players in the Primary Cells Market?**
A: Key players in the Primary Cells Market include Thermo Fisher Scientific, Merck KGaA, and Lonza Group, among others.

**Q: How do the valuations of Human and Animal Primary Cells compare in 2024?**
A: In 2024, Human Primary Cells were valued at 0.82 USD Billion, while Animal Primary Cells were valued at 1.24 USD Billion.

**Q: What is the projected growth for Hematopoietic Cells from 2024 to 2035?**
A: Hematopoietic Cells are projected to grow from 0.5 USD Billion in 2024 to 1.3 USD Billion by 2035.

**Q: Which end user segment is expected to grow the most by 2035?**
A: Pharmaceutical and Biotechnology Companies are expected to grow from 1.24 USD Billion in 2024 to 3.24 USD Billion by 2035.

**Q: What is the valuation of the Skin Cells segment in 2024?**
A: The Skin Cells segment was valued at 0.4 USD Billion in 2024.

**Q: How does the market for Research Institutes compare to Pharmaceutical Companies in 2024?**
A: In 2024, Research Institutes were valued at 0.82 USD Billion, while Pharmaceutical and Biotechnology Companies were valued at 1.24 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/primary-cells-market-6296*